Related references
Note: Only part of the references are listed.Role of the Bone Marrow Microenvironment in Drug Resistance of Hematological Malignances
Alireza Hosseini et al.
CURRENT MEDICINAL CHEMISTRY (2022)
gp130 Cytokines Activate Novel Signaling Pathways and Alter Bone Dissemination in ER plus Breast Cancer Cells
Tolu Omokehinde et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2022)
Structure-activity relationship study of DEL-22379: ERK dimerization inhibitors with increased safety
Yang Yang et al.
MOLECULAR DIVERSITY (2021)
Mini review: The FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer
Fatemeh Khojasteh Poor et al.
Breast Disease (2021)
MEK inhibitor resistance mechanisms and recent developments in combination trials
E. Kun et al.
CANCER TREATMENT REVIEWS (2021)
Discovery of novel BTK PROTACs for B-Cell lymphomas
Yunpeng Zhao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Advances in De Novo Drug Design: From Conventional to Machine Learning Methods
Varnavas D. Mouchlis et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Structure based designing of thiazolidinone-pyrimidine derivatives as ERK2 inhibitors: Synthesis and in vitro evaluation
S. Pathania et al.
SAR AND QSAR IN ENVIRONMENTAL RESEARCH (2021)
Deep Scoring Neural Network Replacing the Scoring Function Components to Improve the Performance of Structure-Based Molecular Docking
Lijuan Yang et al.
ACS CHEMICAL NEUROSCIENCE (2021)
Genome wide CRISPR screening reveals a role for sialylation in the tumorigenesis and chemoresistance of acute myeloid leukemia cells
Dong-hee Lee et al.
CANCER LETTERS (2021)
NMR Based SARS-CoV-2 Antibody Screening
Marta Schoenle et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2021)
Analysis of electric cigarette liquid effect on mouse brain tumor growth through EGFR and ERK activation
Hyung Joon Kwon et al.
PLOS ONE (2021)
Quantitative Structure-Activity Relationship Modeling of the Amplex Ultrared Assay to Predict Thyroperoxidase Inhibitory Activity
Domenico Gadaleta et al.
FRONTIERS IN PHARMACOLOGY (2021)
WWOX and Its Binding Proteins in Neurodegeneration
Che-Yu Hsu et al.
CELLS (2021)
Mitogen-Activated Protein Kinase Pathway in Amyotrophic Lateral Sclerosis
T. G. Sahana et al.
BIOMEDICINES (2021)
Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
Filip Janku et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Recent Trends in Drug Design and Discovery
Devadasan Velmurugan et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2020)
The ERK1/2 inhibitor, JSI-1187, demonstrates preclinical efficacy in tumor models with MAPK pathway mutations
Ao Li et al.
CANCER RESEARCH (2020)
Combining free energy calculations with tailored enzyme activity assays to elucidate substrate binding of a phospho-lysine phosphatase
Anett Hauser et al.
CHEMICAL SCIENCE (2020)
Targeting Alterations in the RAF-MEK Pathway
Rona Yaeger et al.
CANCER DISCOVERY (2019)
Activation loop dynamics are controlled by conformation-selective inhibitors of ERK2
Laurel M. Pegram et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)
Richard A. Ward et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Multi-Target Chemometric Modelling, Fragment Analysis and Virtual Screening with ERK Inhibitors as Potential Anticancer Agents
Amit Kumar Halder et al.
MOLECULES (2019)
Adipose stem cell crosstalk with chemo-residual breast cancer cells: implications for tumor recurrence
Matthew A. Lyes et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Lidocaine inhibits melanoma cell proliferation by regulating ERK phosphorylation
Jun Chen et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2-d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5
Duy Nguyen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance
Ida Aronchik et al.
MOLECULAR CANCER RESEARCH (2019)
Galectin-9 Mediates HIV Transcription by Inducing TCR-Dependent ERK Signaling
Florent Colomb et al.
FRONTIERS IN IMMUNOLOGY (2019)
Importance of protein flexibility in ranking ERK2 Type I1/2 inhibitor affinities: a computational study
Yuzhen Niu et al.
RSC ADVANCES (2019)
Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology
Sobhana Babu Boga et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies
Boaz Mendzelevski et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2
Tom D. Heightman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Andrew M. Kidger et al.
PHARMACOLOGY & THERAPEUTICS (2018)
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
Sobhana Babu Boga et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Serum deprivation/starvation leads to reactivation of HIV-1 in latently infected monocytes via activating ERK/JNK pathway
Rameez Raja et al.
SCIENTIFIC REPORTS (2018)
Identification of Therapeutically Active Molecules against Anthrax through Structure and Ligand based Drug Design
Sisir Nandi et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2018)
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
Sunilkumar Kakadia et al.
ONCOTARGETS AND THERAPY (2018)
Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point
Richard A. Ward et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Ursula A. Germann et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Structure-Guided Strategy for the Development of Potent Bivalent ERK Inhibitors
Bernhard C. Lechtenberg et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Following the Lead from Nature with Covalent Inhibitors
Roman Lagoutte et al.
CHIMIA (2017)
JNK/AP-1 activation contributes to tetrandrine resistance in T-cell acute lymphoblastic leukaemia
Jun-Ting Liou et al.
ACTA PHARMACOLOGICA SINICA (2017)
KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors
Francis Burrows et al.
CANCER RESEARCH (2017)
Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations
Shripad V. Bhagwat et al.
CANCER RESEARCH (2017)
RAS Proteins and Their Regulators in Human Disease
Dhirendra K. Simanshu et al.
CELL (2017)
Revealing the molecular mechanism of different residence times of ERK2 inhibitors via binding free energy calculation and unbinding pathway analysis
Yuzhen Niu et al.
CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS (2016)
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
Vivek Asati et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development
James F. Blake et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers
Jongwon Lim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes
Ana Herrero et al.
CANCER CELL (2015)
Discovery of Highly Potent, Selective, and Efficacious Small Molecule Inhibitors of ERK1/2
Li Ren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2
Richard A. Ward et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
Leanne G. Ahronian et al.
CANCER DISCOVERY (2015)
Computational design, chemical synthesis, and biological evaluation of a novel ERK inhibitor (BL-EI001) with apoptosis-inducing mechanisms in breast cancer
Bo Liu et al.
ONCOTARGET (2015)
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2
James F. Blake et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Recent progress in the identification of BRAF inhibitors as anti-cancer agents
Hala Bakr El-Nassan
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Assessing an Ensemble Docking-Based Virtual Screening Strategy for Kinase Targets by Considering Protein Flexibility
Sheng Tian et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2014)
Discovery of Novel, Dual Mechanism ERK Inhibitors by Affinity Selection Screening of an Inactive Kinase
Yongqi Deng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
In silico screening and study of novel ERK2 inhibitors using 3D QSAR, docking and molecular dynamics
Sofiene Larif et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2014)
A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics
Apirat Chaikuad et al.
NATURE CHEMICAL BIOLOGY (2014)
Afatinib: First Global Approval
Rosselle T. Dungo et al.
DRUGS (2013)
2D-and 3D-QSAR studies of a series of benzopyranes and benzopyrano[3,4b][1,4]-oxazines as inhibitors of the multidrug transporter P-glycoprotein
Ishrat Jabeen et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2013)
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
Erick J. Morris et al.
CANCER DISCOVERY (2013)
Application of Affinity Selection-Mass Spectrometry Assays to Purification and Affinity-Based Screening of the Chemokine Receptor CXCR4
Charles E. Whitehurst et al.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING (2012)
ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
Georgia Hatzivassiliou et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Structure tuning of pyrazolylpyrrole derivatives as ERK inhibitors utilizing dual tools; 3D-QSAR and side-chain hopping
Mi-hyun Kim et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Distinct patterns of activation-dependent changes in conformational mobility between ERK1 and ERK2
Adam Y. Ring et al.
INTERNATIONAL JOURNAL OF MASS SPECTROMETRY (2011)
The Role of ERK1/2 Signaling Pathway in Nef Protein Upregulation of the Expression of the Intercellular Adhesion Molecule 1 in Endothelial Cells
Yang Fan et al.
ANGIOLOGY (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Structure-Guided Design of Potent and Selective Pyrimidylpyrrole Inhibitors of Extracellular Signal-Regulated Kinase (ERK) Using Conformational Control
Alex M. Aronov et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Microvessel vascular smooth muscle cells contribute to collagen type I deposition through ERK1/2 MAP kinase, αvβ3-integrin, and TGF-β1 in response to ANG II and high glucose
Souad Belmadani et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2008)
Affinity selection-mass spectrometry screening techniques for small molecule drug discovery
D. Allen Annis et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2007)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex
M Ohori et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Calpain mediates calcium-induced activation of the Erk1,2 MAPK pathway and cytoskeletal phosphorylation in neurons - Relevance to Alzheimer's disease
Veeranna et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK-1/2, and p70 S6, similar to that in Alzheimer's disease
JJ Pei et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
The associated regulators and signal pathway in rIL-16/CD4 mediated growth regulation in Jurkat cells
XM Zhang et al.
CELL RESEARCH (2002)
HIV Nef increases T cell ERK MAP kinase activity
JA Schrager et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
